Clinical Trials Browser

INDUSTRY × catumaxomab × Gynecologic × Clear all

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00563836 2012-10-03

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Phase 2 Completed

41 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00377429 2012-07-19

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Phase 2 Completed

47 enrolled 11 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00836654 2009-02-05

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Phase 2/3 Completed

258 enrolled

BreastGastrointestinalGynecologic

EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)

Clinical Trials

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group